The effects of FK506 on refractory inflammatory myopathies

Acta Neurologica Belgica

Volumn 111, Issue 3, 2011, Pages 188-194

  Mitsui, Takao ^a,b   Kuroda, Yukiko ^a,b   Ueno, Shu ichi ^b   Kaji, Ryuji ^b  

^a Yoshinogawa   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cell culture; Dermatomyositis; Lymphocytes; Polymyositis; T cell receptor excision circle; Trec

Indexed keywords

CREATINE KINASE; T LYMPHOCYTE RECEPTOR; TACROLIMUS;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL CULTURE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DIABETIC PATIENT; DRUG EFFECT; HUMAN; MEDICAL RESEARCH; OBSERVATIONAL STUDY; POLYMYOSITIS; REFRACTORY PERIOD; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 80054114292     PISSN: 03009009     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Mastaglia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory myopathies: clinical, diagnostic and therapeutic aspects. Muscle nerve. 2003;27:407-425.
2. Hilton-Jones D. Diagnosis and treatment of inflammatory muscle diseases. J Neurol neurosurg Psychiatry. 2003;74 (suppl 2):ii25-ii31.
3. Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann neurol 1991;29: 498-507.
4. Grundtman C, Malmström V, Lundberg IE. Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis res Ther. 2007;9:208.
5. Bohan A, Peter JB. Polymyositis and dermato-myositis (second of two parts). N engl j Med. 1975; 292:403-407.
6. Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine. 1977; 56:255-286.
7. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP. Inclusion body myositis and myopathies. Ann neurol. 1995;38:705-713.
8. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N engl j Med. 1993;329:1993-2000.
9. Mitsui T, Kuroda Y, Kunishige M, Matsumoto T. Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med. 2005;44:1197-1199.
10. Buckley C, Douek D, Newsom-Davis J, Vincent A, Willcox N. Mature, long-lived Cd4+ and Cd8+ T cells are generated by the thymoma in myasthenia gravis. Ann neurol 2001;50:64-72.
11. Loeffler J, Bauer R, Hebart H, Douek DC, Rauser G, Bader P, Einsele H. Quantification of T-cell receptor excision circle DNA using fluorescence resonance energy transfer and the LightCycler system. J immunol Methods. 2002;271:167-175.
12. Horigome A, Hirano T, Oka K. Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells. Immunopharmacology. 1998;39:21-30.
13. Benveniste O, Chérin P, Maisonobe T, Merat R, Chosidow O, Mouthon L, Guillevin L, Flahault A, Burland MC, Klatzmann D, Herson S, Boyer O. Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J immunol. 2001;167:3521-3529.
14. Mitsui T, Kunishige M, Ichimiya M, Shichijo K, Endo I, Matsumoto T. Beneficial effect of tacrolimus on myasthenia gravis with thymoma. Neurologist. 2007;13:83-86.
15. Ponseti JM, Gamez J, Azem J, López-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann n Y acad sci. 2008;1132:254-263.
16. Sempowski G, Thomasch J, Gooding M, Hale L, Edwards L, Ciafaloni E, Sanders D, Massey J, Douek D, Koup R, Haynes B. Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis. J immunol. 2001;166:2808-2817.
17. Tada M, Shimohata T, Tada M, Oyake M, Igarashi S, Onodera O, Naruse S, Tanaka K, Tsuji S, Nishizawa M. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis. J neurol sci. 2006;247:17-20.
18. Utsugisawa K, Nagane Y, Yonezawa H, Obara D, Kondoh R, Tohgi H. Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells. Muscle nerve. 2003;27:245-248
19. Allison AC. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacol. 2000;47;63-83.
20. Bierer BE, Holländer G, Fruman D, Burakoff SJ. Cyclosporin a and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr opin immunol. 1993;5:763-773.
21. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin a and FK506. Immunol Today. 1992; 13:136-142.
22. Thewissen M, Somers V, Venken K, Linsen L, van Paassen P, Geusens P, Damoiseaux J, Stinissen P. Analyses of immunosenescent markers in patients with autoimmune disease. Clin immunol. 2007;123: 209-18.
23. Armengol MP, Sabater L, Fernández M, Ruíz M, Alonso N, Otero MJ, Martínez-Cáceres E, Jaraquemada D, Pujol-Borrell R. Influx of recent thymic emigrants into autoimmune thyroid disease glands in humans. Clin exp immunol. 2008;153:338-350.
24. Thewissen M, Linsen L, Somers V, Geusens P, Raus J, Stinissen P. Premature immunosenescence in rheumatoid arthritis and multiple sclerosis patients. Ann n Y acad sci. 2005;1051:255-62.
25. Hug A, Korporal M, Schröder I, Haas J, Glatz K, Storch-Hagenlocher B, Wildemann B. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J immunol. 2003;171:432-437.
26. Prelog M, Schwarzenbrunner N, Sailer-Höck M, Kern H, Klein-Franke A, Ausserlechner MJ, Koppelstaetter C, Brunner A, Duftner C, Dejaco C, Strasak AM, Müller T, Zimmerhackl LB, Brunner J. Premature aging of the immune system in children with juvenile idiopathic arthritis. Arthritis rheum. 2008;58:2153-2162.